Evidence map›Paper›PMID 24989706›Full record

ArticleDiabetes care2014

Contributors to mortality in high-risk diabetic patients in the Diabetes Heart Study.

Amanda J Cox, Fang-Chi Hsu, Barry I Freedman, David M Herrington, Michael H Criqui, J Jeffrey Carr, Donald W Bowden

Open access · bronzeAbstract read
In one paragraph

Article in Diabetes care, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Association between inflammatory obesity phenotypes, FTO-rs9939609, and cardiovascular risk factors in patients with type 2 diabetes.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2020
    Article
  4. Article
  5. Article
  6. Article
  7. Determinants of mortality in patients with type 2 diabetes: a review.Reviews in endocrine & metabolic disorders · 2016
    Review
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Amanda J CoxCenter for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, NC Center for Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston-Salem, NC Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC.
Fang-Chi HsuDepartment of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC.
Barry I FreedmanDepartment of Internal Medicine-Nephrology, Wake Forest School of Medicine, Winston-Salem, NC.
David M HerringtonDepartment of Internal Medicine-Cardiology, Wake Forest School of Medicine, Winston-Salem, NC.
Michael H CriquiDepartment of Family and Preventive Medicine, University of California, San Diego, La Jolla, CA.
J Jeffrey CarrDepartment of Radiologic Sciences, Wake Forest School of Medicine, Winston-Salem, NC.
Donald W BowdenCenter for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, NC Center for Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston-Salem, NC Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC dbowden@wakehealth.edu.
Wake Forest University · USUniversity of California, San Diego · US

Funding

Epidemiology of cardiovascular disease in diabetesR01HL067348 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BOWDEN, DONALD W · 2001 to 2004
$4.3M
Genetic Epidemiology of Cerebrovascular Disease and Cognition in DiabetesR01NS058700 · NINDS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BOWDEN, DONALD W · 2008 to 2012
$3.0M
Whole Genome Association Analysis of the Diabetes Heart StudyR01HL092301 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BOWDEN, DONALD W · 2010 to 2013
$2.7M
NHLBI NIH HHS R01 HL067348NHLBI NIH HHS R01 HL092301NHLBI NIH HHS R01-HL-092301NHLBI NIH HHS R01-HL-67348NINDS NIH HHS R01 NS058700NINDS NIH HHS R01-NS-058700
6 · The paper itself

Abstract

objectiveNot all individuals with type 2 diabetes and high coronary artery calcified plaque (CAC) experience the same risk for adverse outcomes. This study examined a subset of high-risk individuals based on CAC >1,000 mg (using a total mass score) and evaluated whether differences in a range of modifiable cardiovascular disease (CVD) risk factors provided further insights into risk for mortality. RESEARCH DESIGN AND

methodsWe assessed contributors to all-cause mortality among 371 European American individuals with type 2 diabetes and CAC >1,000 from the Diabetes Heart Study (DHS) after 8.2 ± 3.0 years (mean ± SD) of follow-up. Differences in known CVD risk factors, including modifiable CVD risk factors, were compared between living (n = 218) and deceased (n = 153) participants. Cox proportional hazards regression models were used to quantify risk for all-cause mortality.

resultsDeceased participants had a longer duration of type 2 diabetes (P = 0.02) and reduced use of cholesterol-lowering medications (P = 0.004). Adjusted analyses revealed that vascular calcified plaque scores were associated with increased risk for mortality (hazard ratio 1.31-1.63; 3.89 × 10(-5) < P < 0.03). Higher HbA1c, lipids, and C-reactive protein and reduced kidney function also were associated with a 1.1- to 1.5-fold increased risk for mortality (3.45 × 10(-6) < P < 0.03) after adjusting for confounding factors.

conclusionsEven in this high-risk group, vascular calcification and known CVD risk factors provide useful information for ongoing assessment. The use of cholesterol-lowering medication seemed to be protective for mortality.

Indexed as

AgedCardiovascular DiseasesCause of DeathCoronary Artery DiseaseC-Reactive ProteinDiabetes Mellitus, Type 2Diabetic AngiopathiesFemaleFollow-Up StudiesHumansMaleMiddle AgedPlaque, AtheroscleroticRisk FactorsVascular CalcificationWhite PeopleC-Reactive Protein

Identifiers

PMID24989706
PMCPMC4392938
OpenAlexW2158136577

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.